Zogenix to Participate in the BofA Securities 2021 Healthcare Conference
Zogenix, a biopharmaceutical company focused on rare diseases, announced a virtual fireside chat featuring CEO Stephen J. Farr and CFO Michael Smith on May 13, 2021, at 3:30 PM ET during the BofA Securities 2021 Healthcare Conference. The event will be webcast live and archived for 90 days on Zogenix's Investor Relations website. Zogenix is known for its first therapy, FINTEPLA, which treats Dravet syndrome. The company is also advancing therapies for Lennox-Gastaut syndrome and TK2 deficiency, alongside development initiatives with Tevard Biosciences for genetic epilepsies.
- None.
- None.
EMERYVILLE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a virtual fireside chat on Thursday, May 13, 2021, at the BofA Securities 2021 Healthcare Conference.
| Zogenix Presentation Details | |
| Date: | Thursday, May 13, 2021 |
| Time: | 3:30 PM Eastern Time |
The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.
About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
CONTACTS:
Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com
Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com
Media
Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com
FAQ
When is Zogenix's virtual fireside chat scheduled?
Who will be participating in the Zogenix fireside chat?
Where can I watch the Zogenix fireside chat?
What is FINTEPLA and its significance for Zogenix?
What other therapies is Zogenix developing?
